Chardan Capital Rates EyePoint (EYPT) buy, $65 Price Target

Chardan Capital has reiterated its buy rating on EyePoint, Inc. with a price target of $65, a 354.55% upside from the current price.

By EarningsIQ Research Desk · Published Jul 1, 2026, 9:01 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Chardan Capital rated EyePoint, Inc. ($EYPT) "buy" with a $65 price target on July 1, 2026.

Since the rating, $EYPT is up 6.1% after 1 week, down 7.2% after 1 month and down 77.3% to date (from the $13.20 close on Jul 1, 2026).

EYPT EyePoint, Inc.

$2.99 -82.89% year to date

Daily close · Oct 16, 2026

Key Points

Chardan Capital reiterated its buy rating for EyePoint, Inc. (EYPT) on July 1, 2026, with a price target of $65.
Chardan Capital's $65 price target implies 354.55% upside from EyePoint, Inc.'s ($EYPT) current $14.30 share price.
EyePoint, Inc. shares traded at $14.30 on Wednesday, with a market cap of around $1.2 billion and a 52-week range between $8.96 and $19.11.
Institutional investors like Suvretta Capital and BlackRock have adjusted their positions in EyePoint, Inc., reflecting varied levels of confidence.

Get $EYPT trade alerts by text

We text you when insiders, Congress or big funds trade $EYPT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated EyePoint, Inc. alert may contain errors. Disclosures

Chardan Capital has reiterated its buy rating on EyePoint, Inc. (NasdaqGM: EYPT), maintaining a price target of $65. This update was issued on July 1, 2026, by analyst Andreas Argyrides. Shares of EyePoint traded at approximately $14.30 on Wednesday.

Other Institutional Activity in EyePoint, Inc.

Several institutional investors have made changes to their holdings in EyePoint, Inc. Suvretta Capital Management increased its stake by 468,690 shares, ending with 8,296,375 shares valued at about $106.9 million. BlackRock, Inc. also added 389,465 shares, bringing its total to 7,177,337 shares worth roughly $92.5 million. In contrast, Federated Hermes, Inc. trimmed its holdings by 347,844 shares, now holding 5,669,589 shares valued at $73.1 million. Meanwhile, Janus Henderson Group PLC made a notable increase, adding 663,439 shares to reach a total of 3,601,168 shares valued at $46.4 million.

EyePoint, Inc. Stock Up 271.4%

On Wednesday, shares of EyePoint, Inc. traded near $14.30. The company, with a market capitalization of around $1.2 billion, operates in the biotechnology sector. EyePoint's stock has seen a 52-week low of $8.96 and a high of $19.11. Its 50-day moving average stands at $13.22, while the 200-day moving average is $14.12. The company has a current ratio of 6.66 and a quick ratio of 5.97, indicating strong liquidity.

12-month forecast

$EYPT price target

EyePoint, Inc. daily closes and this analyst's $65 target. Not advice.

Recent Earnings

EyePoint, Inc. reported revenue of $7.6 million, with a modest growth rate of 1.6%. Despite this, the company is not yet profitable, reflected in its negative return on equity of -102.71% and net margin of 0%. The next earnings release is anticipated on August 5, 2026.

Insider Buying and Selling at EyePoint, Inc.

EyePoint's Chief Financial Officer, George Elston, was active on May 25, 2026, selling 3,627 shares at an average price of $12.93. On the same day, he also bought and sold 7,500 shares without a specified price. Chief Medical Officer Ramiro Ribeiro bought 2,437 shares on April 17, 2026, at $8.26 and later sold the same amount at $15.00 under a planned transaction.

Analysts Set New Price Targets

On July 1, 2026, Chardan Capital maintained its buy rating on EyePoint, Inc. with a price target of $65. Previously, on June 24, 2026, Guggenheim reiterated a buy rating with a slightly higher target of $68. RBC Capital and Citigroup have also maintained buy ratings in recent months, with targets of $37 and $35, respectively. The consensus among 12 analysts is a strong buy, with an average target price of $37.

About EyePoint, Inc.

EyePoint, Inc., headquartered in Watertown, Massachusetts, focuses on developing treatments for serious retinal diseases. The company's lead product, DURAVYU, is in Phase 3 trials for conditions like wet age-related macular degeneration and diabetic macular edema. EyePoint utilizes its Durasert E technology for sustained intraocular drug delivery. Dr. Jay S. Duker serves as the CEO, leading a team of 214 employees.

Bottom Line

EyePoint, Inc. continues to attract attention from analysts and institutional investors. Chardan Capital's reiterated buy rating and $65 price target reflect confidence in the company's potential. Investors should note that 13F filings and analyst ratings are backward-looking indicators that provide insights into institutional sentiment and expectations.